HC Wainwright Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Investment analysts at HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $45.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 123.33% from the stock’s current price.

DMRA has been the topic of a number of other reports. Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target on the stock. UBS Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target on the stock. Guggenheim restated a “buy” rating and set a $40.00 target price (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Wedbush initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Thursday, May 28th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Evercore initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Down 3.9%

Shares of NASDAQ:DMRA opened at $20.15 on Thursday. The business’s fifty day simple moving average is $24.68 and its 200-day simple moving average is $25.34. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.45 and a 12-month high of $38.33. The company has a market capitalization of $1.24 billion, a PE ratio of -3.61 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.1 EPS for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in DMRA. Ikarian Capital LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $6,574,000. Jain Global LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,774,000. Remedium Capital Partners LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,772,000. Boothbay Fund Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,204,000. Finally, Connective Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth about $100,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.